Published in final edited form as:

Neurochem Res. 2019 March ; 44(3): 636–649. doi:10.1007/s11064-018-2531-x.

Gβγ SNARE interactions and their behavioral effects

Simon Alford¹, Heidi Hamm², Shelagh Rodriguez¹, and Zack Zurawski²

¹Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60612-7308

²Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6600

Abstract

Presynaptic terminals possess interlocking molecular mechanisms that control exocytosis. An example of such complexity is the modulation of release by presynaptic G Protein Coupled Receptors (GPCRs). GPCR ubiquity at synapses - GPCRs are present at every studied presynaptic terminal – underlies their critical importance in synaptic function. GPCRs mediate presynaptic modulation by mechanisms including via classical Gα effectors, but membrane-delimited actions of Gβγ can also alter probability of release by altering presynaptic ionic conductances. This directly or indirectly modifies action potential-evoked presynaptic Ca²⁺ entry. In addition, Gβγ can interact directly with SNARE complexes responsible for synaptic vesicle fusion to reduce peak cleft neurotransmitter concentrations during evoked release. The interaction of Gβγ with SNARE is displaced via competitive interaction with C2AB-domain containing calcium sensors such as synaptotagmin I in a Ca²⁺-sensitive manner, restoring exocytosis. Synaptic modulation of this form allows selective inhibition of postsynaptic receptor-mediated responses, and this, in combination with Ca²⁺ sensitivity of Gβγ effects on SNARE complexes allows for specific behavioral outcomes. One such outcome mediated by 5-HT receptors in the spinal cord seen in all vertebrates shows remarkable synergy between presynaptic effects of Gβγ and postsynaptic 5-HT-mediated changes in activation of Ca²⁺-dependent K⁺ channels. While acting through entirely separate cellular compartments and signal transduction pathways, these effects converge on the same effect on locomotion and other critical functions of the central nervous system.

2) Introduction

Synapses are inherently plastic and adaptable, both in the long-term to create memories, but also in the short term as a means for shaping patterns of activity that underlie complex behaviors, and to allow short-term adaptation. While both pre- and postsynaptic terminals may generate this adaptability, much of the focus placed on synaptic plasticity has been on the postsynaptic terminal and modifications to receptor type, numbers and placement. Less emphasis has been placed on the presynaptic terminal and presynaptic mechanisms of plasticity. Nevertheless, one form of presynaptic plasticity is likely ubiquitous at all presynaptic terminals - synaptic modulation mediated by pertussis toxin-sensitive (Gi/o) G proteins [1]. Various neurotransmitters modulate release from presynaptic terminals [2, 3]

many mediated by GPCRs [4–7] that are activated by many different neurotransmitters. This modulation may occur at axo-axonic synapses [8, 9] or may result from neurotransmitters released at paracrine terminals to diffuse in the tissue [10]. Other GPCRs at presynaptic terminals may be activated by neurotransmitter released in that same terminal, and are referred to as autoreceptors, which may serve as a feedback mechanism at the presynaptic terminal. These have been implicated in both negative [11–13] and positive [6, 14] modulation of neurotransmitter release.

GPCR-mediated short-term synaptic plasticity has been widely considered to result from G protein modulation of the voltage-gated Ca^{2+} channels (VGCCs) responsible for evoking synaptic vesicle fusion [15, 16]. Modulation of VGCCs is now known to be mediated by a direct $\text{G}\beta\gamma$ subunit interaction with a number of VGCC subtypes [17]. Although these mechanisms were assumed to take place in synapses, it was not until 1995 that Wu and Saggau directly demonstrated that this occurs in presynaptic terminals [18]. A number of other researchers had demonstrated that $\text{G}_{i/o}$ signaling at presynaptic terminals must involve mechanisms distinct from modulation of VGCCs. The first such indication was that GPCRs inhibit spontaneous release of neurotransmitter release independently of presynaptic Ca^{2+} entry was the observation of inhibition of the frequency of spontaneous neurotransmitter release events in the absence of evoked Ca^{2+} entry [19, 20]. It is now clear that membrane-delimited G protein signaling also directly targets the SNARE complex responsible for vesicle fusion. We will discuss this signaling, its complex interaction with GPCR modulation of presynaptic Ca^{2+} channels and consequent effects on presynaptic integration.

Membrane-delimited $\text{G}\beta\gamma$ targets that alter presynaptic Ca^{2+} entry

GPCRs which inhibit neurotransmitter release have been widely studied. These include both membrane-delimited targets of $\text{G}\beta\gamma$ and modulation through activation of downstream second messenger effectors. GPCRs involved in membrane-delimited presynaptic inhibition include GABA_B receptors [21], tachikinin receptors [22], adrenergic receptors [17, 23], metabotropic glutamate receptors (mGluRs) [24], opioid receptors [25], 5-HT receptors [7] and dopamine receptors [26].

Cellular mechanisms involved in neuromodulation at the presynaptic terminal are not particularly well-understood because of the difficulties in recording from vertebrate presynaptic terminals, which tend to be very small. Uncertainty over the mechanisms by which G proteins alter neurotransmitter release also reflects the variety of effector targets of G protein activation by G protein-coupled receptors [27]. Due to a lack of presynaptic access, most molecular studies of the detailed mechanisms come from either transfection of the relevant proteins into cultured cell lines and *Xenopus* oocytes, or from electrophysiological measurements from neuronal cell bodies. However, membrane-delimited inhibition of neurotransmission mediated by G protein $\beta\gamma$ subunits at the presynaptic terminal have been hypothesized to be mediated by various mechanisms directed to presynaptic ion channel conductances all of which lead to reduced presynaptic Ca^{2+} entry (Fig 1A,B).

- A. $\text{G}\beta\gamma$ mediated inhibition of synaptic transmission may act by a direct action of G protein $\beta\gamma$ subunit on the gating of voltage-gated Ca^{2+} channels (VGCCs) [16,

28–31]. $G\beta\gamma$ -mediated inhibition of VGCCs reduces presynaptic Ca^{2+} entry, causing a reduction in probability of release. This has been shown directly using Ca^{2+} imaging in hippocampal pyramidal neuron terminals [18] [32], and electrophysiologically at the calyx synapse of Held [33].

- B.** Membrane-delimited $G\beta\gamma$ might also inhibit neurotransmitter release by an indirect action. For example, GIRKs located at the presynaptic terminal, and activated by $G\beta\gamma$, could serve to reduce the amplitude of the action potential and repolarize the presynaptic terminal more quickly, allowing fewer Ca^{2+} channels to open. $G\beta\gamma$ activates GIRKs in neuronal cell bodies and in transfected cell lines and *Xenopus* oocytes [34–36], and some studies indicate that this can occur presynaptically [37] although direct evidence of a presynaptic role has not been presented. $G\beta\gamma$ can also directly modulate voltage-gated Na^+ channels [38] to alter persistent Na^+ currents [44], however, no direct evidence for a presynaptic location of this effect has yet been presented.

Membrane-delimited targets downstream of presynaptic Ca^{2+} entry

Many G protein effectors have been implicated in modulation of synaptic vesicle fusion. It is possible to postulate multiple sites within the presynaptic terminal at which G proteins may interfere with neurotransmitter release both through membrane-delimited actions of $G\beta\gamma$, and through second messenger effectors. G proteins may inhibit exocytotic processes in different ways including modulation upstream, distal to, or at the point of Ca^{2+} entry. Exocytotic processes in pancreatic β cells, peritoneal mast cells, chromaffin cells, PC12 cells and secretory granules are directly regulated by G proteins [39–41]. The ability of G proteins to mediate inhibition of neurotransmitter release by directly targeting the release apparatus following evoked Ca^{2+} entry was first demonstrated by Silinsky [42] in the neuromuscular junction. Spontaneous exocytotic events, where exocytosis occurs independently of Ca^{2+} entry, can be detected by recording miniature excitatory/inhibitory postsynaptic currents (mE/IPSCs). Measurements of mE/IPSCs allow the exocytotic modulatory processes that occur independently of Ca^{2+} entry to be isolated and studied, unlike evoked EPSCs which require Ca^{2+} entry. These mE/IPSCs have been shown to be regulated by many GPCRs [42–45], including serotonin receptors [1, 46], muscarinic receptors, mGluRs and GABA_B receptors. Evidence that these effects are mediated downstream of Ca^{2+} entry to the presynaptic terminal are supported by experiments in which transmitter release evoked following membrane permeabilization with ionomycin or α -latrotoxin is inhibited by GPCRs [47] as well as by experiments in permeabilized cells in which $G\beta\gamma$ inhibits exocytosis [48]. Indeed, that latter experiment also pointed strongly to a membrane-delimited effect, because the experiments were performed on cell membranes that lacked a cytosolic compartment [49]. These results pointed to a more direct mechanism by which GPCRs might modulate neurotransmitter release (Fig 1C).

The SNARE complex as a target for signaling

Presynaptic GPCRs, SNARE complexes, and fusogenic Ca^{2+} -sensor proteins, along with other SNARE complex-associated proteins, form molecular machines that evoke exocytosis and shape complex synaptic patterns. Presynaptic modulation requires precise interactions of

receptors and effectors with the exocytotic machinery. The resultant short-term plasticity is critical to neural function; it shapes responses governing sensation [50, 51], motor output [9, 52] and oscillations in cognition and neuropsychiatric disorders [53, 54].

There are numerous presynaptic molecular targets that evoke short-term plasticity. Plasticity may be caused by changes in probability [55], vesicle priming [56], the sub-synaptic locations of release [57], or the fusion process itself [58, 59]. However, while all of these properties are modified by GPCRs [60, 61] activity leading to synaptic transmission may also modify the properties of GPCR signaling. For example, high frequency stimulation of a presynaptic terminal may alter its cytosolic Ca^{2+} concentration which may modify GPCR targets downstream of Ca^{2+} entry. Multiple GPCRs are present at all synapses, as auto-[62], and hetero-receptors [63], but ultimately their targets are the processes of synaptic vesicle fusion.

Synaptic vesicle fusion is a form of exocytosis and requires protein-protein, protein-lipid and lipid-lipid interactions, each of which provides a possible target for presynaptic modulation. Proteins include the SNARE proteins (Fig 2A) [64, 65] comprising the vesicular- ν -SNARE, synaptobrevin that contains a SNARE motif that binds to coiled-coil SNARE motifs in the dimer of two target plasmalemma t -SNAREs, syntaxin1A and SNAP25 [64, 65]. Other fusion machinery proteins are voltage-gated Ca^{2+} channels (VGCCs) [66], fusogenic Ca^{2+} sensors [67, 68], and proteins that modify vesicle docking, priming, and fusion (e.g. munc18 [69, 70], munc13 [71, 72], complexin [73] and homomeric [74, 75] and heteromeric G proteins [76–78]). Fusion is triggered by Ca^{2+} sensors – particularly synaptotagmins comprising N-terminal transmembrane domains and tandem Ca^{2+} -binding domains [79, 80] – which cause synchronous [67], and asynchronous synaptic vesicle fusion [81, 82], and frequency-dependent-modulation of synaptic output [83]. In CA1 pyramidal cells, synaptotagmin1 triggers synchronous fusion. It binds SNARE complexes at low affinity in zero or resting Ca^{2+} concentrations [79, 80, 84–86], but binds at higher affinity in elevated Ca^{2+} [87–89] as it simultaneously interacts with lipids [85, 90, 91]. The resultant exocytosis is modulated by $\text{G}_{i/o}$ -coupled GPCRs, with both the $\text{G}\alpha$ and $\text{G}\beta\gamma$ G protein subunits activating discrete pathways [60]. In particular, $\text{G}\beta\gamma$ injected into presynaptic terminals or released by presynaptic GPCRs can rapidly and reversibly inhibit exocytosis [61, 92–94] or cause long term plasticity [61, 95, 96]. It is this reversible membrane-delimited $\text{G}\beta\gamma$ -mediated inhibition (Fig 2A) that is discussed in this review and which may act throughout the sequence of events leading to evoked release, from initial Ca^{2+} entry to the SNARE complex-mediated lipid fusion event.

The SNARE complex as a $\text{G}\beta\gamma$ target

$\text{G}\beta\gamma$ interacts directly with the presynaptic SNARE complex to interfere with synaptotagmin1 binding and modify vesicle fusion. In the experimentally accessible lamprey giant reticulospinal synapse (Fig 2B), a number of agonists inhibit synaptic release of glutamate, including dopamine receptors, metabotropic glutamate receptors and 5-HT receptors. However, agonists to most of these receptors act without altering presynaptic Ca^{2+} entry [6, 97] and neurotransmitter release evoked by presynaptic flash photolysis of Ca^{2+} is inhibited by 5-HT and $\text{G}\beta\gamma$ at these synapses to the same extent as for responses elicited by

action potential [98] indicating that release is inhibited “downstream” of an effect on VGCCs. Nevertheless, $G\beta\gamma$ released by activation of 5-HT_{1B/1D} like receptors [99] inhibits neurotransmission by a membrane-delimited action [7, 97]. Indeed, direct injection of $G\beta\gamma$ buffering peptide, phosducin, or C-terminal fragments of G protein receptor kinase 2 (ct-GRK2) [7] prevent GPCR-mediated presynaptic inhibition at lamprey giant synapses (Fig 2E), and a myristoylated G-protein $\beta\gamma$ selective binding peptide (mSIRK) [95] prevents GPCR-mediated synaptic modulation in mammalian hippocampal synapses.

This $G\beta\gamma$ -mediated inhibition proved to be mediated by a direct action at the C-terminal region of SNAP-25 and acts late in the synaptic vesicle fusion cycle at primed vesicles after SNAP-25 is incorporated into ternary SNARE complexes. Botulinum toxins were utilized to identify the specific step in vesicle fusion inhibited by $G\beta\gamma$. These toxins cannot access the ternary SNARE formed as vesicles are primed prior to evoked synaptic transmission [100]. Consequently, Botulinum B toxin (BoNT/B), which cleaves synaptobrevin (Fig 3A–D), has little immediate effect on neurotransmission immediately after its injection into an axon. However, if after toxin injection into the axons, a period of 1Hz stimulation is used to deplete primed vesicles, BoNT/B causes a complete loss of synaptic transmission (Fig 3D). Yet during this period, during which BoNT/B has cleaved unprimed SNAP-25, GPCR activation (using 5-HT as an agonist) still inhibits vesicle fusion and synaptic transmission to the same extent as in controls (Fig 3D). The speed of action of $G\beta\gamma$ -mediated inhibition (less than 20 ms after receptor activation [98]) also points to an effect late in the vesicle cycle. Thus, GPCRs can inhibit release late in the exocytotic/endocytotic cycle after vesicle priming.

The target for $G\beta\gamma$ was also identified using botulinum toxin injected into the giant axon. Botulinum A toxin (BoNT/A) cleaves a C-terminal 9 amino acid fragment from SNAP-25. This leaves a truncated SNAP-25 that can still support synaptic transmission [77, 89], albeit at a reduced amplitude. Thus, in a similar experiment to that using BoNT/B, BoNT/A was injected into lamprey reticulospinal synaptic terminals. After injection and subsequent elimination of primed vesicles with 300 stimuli, synaptic responses were reduced in amplitude. However, this application prevented GPCR mediated presynaptic inhibition (Fig 3E,F) [98]. The BoNT/A sensitivity of this effect of $G\beta\gamma$ provided a starting point to determine how $G\beta\gamma$ mediates presynaptic inhibition of synaptic transmission. It has also enabled this mechanism of presynaptic modulation to be identified in a number of other synapses, and utilizing other GPCRs and agonists [23, 95, 101].

$G\beta\gamma$ competition with Synaptotagmin1 during fusion

To determine functional sites of interaction between $G\beta\gamma$ and SNARE complexes, alanine screening mutagenesis was used to identify critical residues. Residues on the C and N-terminal regions of SNAP-25 proved necessary for its interaction with $G\beta\gamma$, but which after modification, do not interfere with Ca^{2+} -synaptotagmin SNARE interactions [102]. To study the effects of these mutant forms of SNAP-25, the mutations were introduced on a Botulinum E toxin (BoNT/E)-resistant form of SNAP-25 (D179K) and injected into giant axons along with BoNT/E light chain to remove endogenous protein. After 300 stimuli to clear primed vesicles, and subsequent cleavage, SNAP-25 D179K substituted successfully

for the endogenous SNAP-25 supporting synaptic transmission that would otherwise have been lost. After this substitution, 5-HT mediated GPCR activation failed to inhibit neurotransmission [103].

The C-terminal region of SNAP-25 cleaved by BoNT/A represents a site for interaction between synaptobrevin and the ternary SNARE complex to evoke synaptic transmission [89]. Therefore, it was possible that Gβγ and synaptobrevin compete to interact with SNARE complexes at the C-terminal region of the complex. Indeed, Ca²⁺-synaptobrevin binding to the SNARE complex is reduced by Gβγ, consistent with competition between Ca²⁺-synaptobrevin and Gβγ. Furthermore, removal of the C-terminal 9 amino acids from SNAP-25 favors synaptobrevin over Gβγ binding to the t-SNARE complex as well as the ternary SNARE complex [77]. This competition can be recorded in a fluorescence assay with the proteins dissolved in aqueous solution and detergent, but also when SNARE complexes are more physiologically localized into lipid membranes. Anisotropy of fluorescence produced via the binding of fluorescent synaptobrevin 1 to t-SNAREs was detected in lipid bilayers using TIRF imaging of a glass cover slip *supported lipid bilayer*. Addition of Ca²⁺ increased the anisotropy of the synaptobrevin 1 fluorescence. This rise in anisotropy produced via the binding of synaptobrevin 1 to t-SNARE complexes could be reversed in a concentration-dependent manner by purified Gβγ applied in the solution [109] (Fig 4A,B). While the C-terminal 9 residues of SNAP-25 are not highlighted as a critical binding site for synaptobrevin I-SNAP-25 interactions in X-ray crystallographic studies [85, 88], the synaptobrevin molecule's binding site, which is lost after cleavage of the C-terminal 26 residues of SNAP-25 with BoNT/E [89], may overlap with that of Gβγ through a direct steric effect, resulting in competition [102].

If Gβγ competes with Ca²⁺-synaptobrevin binding at SNARE complexes, then it should be possible to reproduce this mechanism in an artificial fusion assay with only lipid, SNARE complexes, synaptobrevin and Gβγ present. This indeed proved possible (Fig 4C,D), and under these circumstances Gβγ inhibits Ca²⁺-synaptobrevin-mediated fusion of t-SNARE and v-SNARE containing vesicles. A reconstituted fusion assay [104–106] was used. Liposomes containing v-SNARE were prepared using recombinant full-length synaptobrevin and a FRET donor-acceptor pair. t-SNARE liposomes contained full-length recombinant rat syntaxin 1A and SNAP25B heterodimers. As the quenched FRET-pair containing liposomes fuse with the unlabeled liposomes, the concentration of the FRET acceptor is lowered, to increase the donor fluorescence. Addition of synaptobrevin 1 (10μM) in Ca²⁺ (1mM) [107] stimulated fusion. Gβγ, inhibited this Ca²⁺-synaptobrevin-1 triggered fusion in a concentration-dependent manner (Fig 4D). This Gβγ-mediated inhibition is also Ca²⁺ sensitive. At higher Ca²⁺ concentrations fusion is more rapid, but Gβγ is less effective in preventing this fusion [113].

This same Ca²⁺ sensitivity of inhibition is seen during synaptic transmission. If Ca²⁺-synaptobrevin interactions with SNARE complexes provide a competitive site for Gβγ to modify synaptic transmission, then it may be hypothesized that GPCR-mediated inhibition is Ca²⁺ sensitive. Indeed, raising the extracellular Ca²⁺ concentration surrounding synapses during evoked synaptic transmission causes a substantially enhanced presynaptic Ca²⁺ transient. At the same time, GPCR mediated presynaptic inhibition is lost [77, 108].

Implications of presynaptic targets of $G\beta\gamma$ in modulating neurotransmitter release

GPCRs can liberate $G\beta\gamma$ into presynaptic terminals and this inhibits neurotransmission, either by inhibiting Ca^{2+} entry to the presynaptic terminal, or by competing with Ca^{2+} -synaptotagmin interaction with the t-SNARE. While the effect of inhibiting Ca^{2+} entry on synaptic transmission is predictable and established – a reduction in neurotransmitter release probability [18], the outcome of $G\beta\gamma$ effects on SNARE complexes is hard to predict. Presynaptic effects on release probability can be demonstrated by examining effects of paired-pulses on synaptic transmission. In a pair of pulses if vesicle fusion occurs on the first pulse, this lowers available primed vesicles for the second pulse and thus release probability. Thus, any synaptic manipulation that reduces release probability allows a relative enhancement of the probability of release on the second pulse. This is demonstrated by reducing Ca^{2+} entry to lamprey giant axons by raising the extracellular Mg^{2+} concentration which enhances paired pulse ratios. In contrast, presynaptic GPCR activation by activating 5-HT receptors has no such effect. Thus, 5-HT receptors on lamprey giant axons reduce neurotransmitter release, but not release probability [109].

Analysis of the quantal size of unitary synaptic events between reticulospinal axons and their postsynaptic targets also demonstrated that 5-HT-mediated inhibition is caused by a reduction in size of unitary EPSCs [59]. Furthermore, FM dye destaining experiments indicate that 5-HT causes vesicles to trap FM1-43 within vesicles that still transiently fuse and release neurotransmitter. In intact lamprey spinal cord, destaining of FM1-43 loaded into giant axon synaptic vesicles could be visualized in the intact spinal cord [110]. Synaptic vesicle clusters were labeled with FM1-43. In control conditions stimulation of these axons caused almost complete destaining. However, this destaining was nearly abolished using the same protocol in 600 nM 5-HT, a dose that only halved the amplitude of EPSCs recorded from these axons. These results suggested that after treatment with 5-HT membrane-bound FM1-43 could not escape vesicles from which, nevertheless, glutamate was released [59].

If, during this incomplete fusion, glutamate can escape from vesicles, because glutamate dissolved in the vesicle interior can escape a transiently formed vesicle pore, but the lipophilic FM1-43 cannot [111], then the vesicle interior must contact the extracellular space to allow glutamate release. Indeed water-soluble molecules in the extracellular space (e.g. sulforhodamine) proved able to permeate these vesicle fusion pores and quench FM1-43 by fluorescence resonance energy transfer (FRET). Thus, introducing sulforhodamine into the extracellular space during application of 5-HT allowed destaining to recover [59]. This strongly implies that vesicles transiently fuse with a kiss-and-run mechanism in the presence of 5-HT, to allow some release of glutamate but trapping FM1-43 in their interior.

Thus, GPCRs that release $G\beta\gamma$ to directly target the SNARE complex do not modify probability of release. An alternative mechanism might be that these receptors modify the concentration of glutamate in the synaptic cleft. Competitive low affinity AMPA receptor antagonists such as kynurenate can be used to test this. [112, 113]. A competitive low affinity antagonist rapidly unbinds from the receptor after binding. If the antagonist affinity is sufficiently low, a portion of an EPSC only partially blocked by such an antagonist will be due to non-equilibrium unbinding of the antagonist from the receptor and its subsequent competitive replacement by synaptically released glutamate [112]. The degree to which

antagonist, unbinding from the AMPA receptor, is replaced by glutamate is dependent on the cleft glutamate concentration. It is therefore possible to monitor changes in cleft glutamate concentration by measuring the degree of low affinity antagonist replacement by glutamate. For example, in kynurenate, if the synaptic cleft glutamate concentration is lowered by 5-HT, there will be less replacement of the antagonist by glutamate and the magnitude of inhibition mediated by the same dose of 5-HT on the EPSC will be greater than under control conditions. Likewise, the extent of inhibition mediated by application of kynurenate will be greater in the presence of 5-HT than during application of kynurenate alone.

This is precisely the outcome obtained from sequential application of kynurenate and 5-HT on paired synaptic responses recorded from stimulation of lamprey giant axons. After recording control responses, an approximately half maximal dose of kynurenate effectively doubled the efficacy of 5-HT to inhibit synaptic transmission [109].

Thus, GPCRs at presynaptic terminals can cause a reduction of the peak concentration of glutamate released into the synaptic cleft during evoked synaptic transmission. This form of synaptic plasticity may differentially modify the activation of different postsynaptic receptors [114, 115]. NMDA receptors with relatively high affinity glutamate interactions and slow unbinding rates at 2 glutamate binding sites are more sensitive to low cleft glutamate concentrations than are AMPA receptors with up to 4 higher affinity glutamate binding sites. Indeed, comparing postsynaptic effects of 5-HT at the lamprey giant synapse demonstrates that 5-HT has both a lower half maximal efficacy and a greater maximal inhibitory effect in inhibiting AMPA receptor-mediated synaptic responses than against NMDA receptor-mediated effects [108, 109] (Fig 5 Ab).

On lamprey reticulospinal axons, 5-HT receptor activation causes $G\beta\gamma$ to compete with Ca^{2+} -synaptotagmin for binding sites upon docked and primed ternary SNARE complexes. While the outcome of this is to reduce the evoked peak synaptic cleft concentration of glutamate during synaptic transmission [109] the efficacy of $G\beta\gamma$ in inhibiting synaptic transmission is reduced by high evoked Ca^{2+} concentrations that can be evoked by trains of stimuli. Physiologically trains of stimuli cause summing Ca^{2+} concentrations in presynaptic terminals which reduces the efficacy 5-HT's inhibitory action at reticulospinal axon terminals [108, 109]. Thus, if short trains of action potentials (eg 10 action potentials at 20Hz) are applied to reticulospinal giant axons, paired EPSCs recorded in their target neurons show a series of EPSCs. In control conditions, the EPSCs at the start of the train are inhibited, however this inhibition is lost towards the end of the train (Fig 5Ac).

The implications of presynaptic targets of GPCRs on behavior

The target for GPCRs and $G\beta\gamma$ on the SNARE complex, thus, opens up a number of complex non-linear effects on synaptic transmission following the activation of presynaptic receptors. The effects of presynaptic inhibition on behavior has not been widely investigated. In the case of 5-HT receptors on reticulospinal and intraspinal glutamatergic terminals in the lamprey spinal cord, this is testable because these terminals form part of an extraordinarily well-understood spinal motor system [116]. Furthermore, the effects of presynaptic 5-HT_{1B/1D} receptors are selective to glutamatergic synapses in the spinal cord, both at reticulospinal synapses and intraspinal excitatory synapse (Fig 5A) and have definable

effects on synaptic transmission. 5-HT_{1B/1D} receptor activation favors NMDA receptor-mediated synaptic transmission which evokes slower locomotion than when AMPA receptors are selectively activated [117–119] and stimulus trains evoke responses that are inhibited at the start but not the end of the train. Computer simulations of the effect of this on locomotion demonstrate a slowing of the locomotor rhythm [120, 121].

To test the effects of presynaptic 5-HT receptors on locomotor behavior, fictive locomotion was evoked by brainstem stimulation of the descending motor command system [122]. This neural correlate of the activity that generates a traveling wave of activity in the lamprey spinal cord and consequently the trunk musculature (Fig 5B) can be evoked in an isolated brainstem/spinal cord preparation by stimulation of the Mesencephalic Locomotor Region with a pulse of pressure-applied glutamate. This caused short episodes of fictive locomotion (Fig 5C), representing the neural output from the spinal locomotor central pattern generators responsible for locomotion. Application of a selective agonist of presynaptic 5-HT_{1B} receptors to the spinal cord modified locomotion, to reduce the frequency of left right alternation (Fig 5Cb,Cc), but without modifying the total output of the spinal cord [108]. This outcome clearly results directly from the cellular effects of 5-HT receptors in the presynaptic terminal, both that the receptor activation favors synaptic activation of NMDA receptors over AMPA which will cause slower fictive locomotion [117, 123], but also because the response to stimulus trains allows recovery from 5-HT-mediated inhibition during the stimulus train. This augmenting synaptic output favors slower locomotor activity in mathematical models of the locomotor pattern generator [120, 121]. From these data, it is apparent that presynaptic 5-HT receptors act as a modulator rather than an inhibitor of activity. This ability to modulate rather than inhibit synaptic output is critical to the function of serotonergic presynaptic modulation. Thus, for example, at a low dose of the glutamate receptor antagonist kynurebate, sufficient to half the amplitude of synaptic responses from giant axons in the spinal cord, locomotion is entirely abolished. Similarly, sparing postsynaptic activation of NMDA receptor-mediated synaptic responses is also critical. Blocking these also prevents fictive locomotion [108]. However, a further striking function of the presynaptic receptors discussed in this review, is that though their site and mechanism of action is entirely distinct from postsynaptic serotonin receptors that respond to the same paracrine release of 5-HT, their effect on behavior is entirely synergistic. Postsynaptic 5-HT receptors also slow the locomotor rhythm, but do so by inhibiting postsynaptic Ca²⁺ activated K⁺ channels [124–128].

Conclusions

Presynaptic G_{i/o} coupled GPCRs are ubiquitous, but signal through a variety of mechanisms. One of those mechanisms, whereby Gβγ targets the SNARE complex to compete with synaptotagmin 1 binding, leads to complex synaptic modulation and a form of circuit plasticity that is extraordinarily synergistic with the activation of postsynaptic serotonin receptors. There is substantial debate on the nature of synaptic vesicle fusion and the protein-lipid machinery that drives this critical synaptic function. Fusion of vesicles may be complete and convey quantal properties to synaptic events [129, 130]. But fusion may also be incomplete and more nuanced [131]. This debate has extended to the present with

evidence that kiss and run fusion [58, 132] can differentially modulate postsynaptic receptor activation [114], while the frequency of this form of transmission has been challenged [139].

Perhaps an answer to this conundrum lies in its target – competing with Ca^{2+} -synaptotagmin interactions at SNARE complexes [77, 102], and the ability of presynaptic receptors to modulate fusion properties of synaptic vesicles, causing kiss-and-run fusion [59, 109]. It would appear that presynaptic GPCR activation provides a variety of routes to evoke synaptic plasticity. In particular $\text{G}\beta\gamma$ interaction with the SNARE complex opens the possibility for sophisticated modulation of synaptic vesicle fusion [59, 101, 133], that this modulation creates complex synaptic modulation far beyond simple changes in release probability [108, 109], and that these synaptic changes have implications for our understanding of circuit functions and behavior [99, 108]. In addition, the capacity to modulate neurotransmitter release independently of changes in presynaptic Ca^{2+} may preserve other effects of Ca^{2+} at the presynaptic terminal even during modulation. The requirement for such complex modulation of neurotransmitter release is apparent from effects on lamprey locomotion – effects that serotonin also causes in mammalian models of locomotion [134, 135]. Thus, both the target of 5-HT-liberated $\text{G}\beta\gamma$ at the SNARE complex in which inhibition is modulated by Ca^{2+} -dependent competition with synaptotagmin, and the effects of $\text{G}\beta\gamma$ on vesicle fusion are necessary to maintain the modulatory role of 5-HT in the spinal cord [108]. If, in contrast, 5-HT merely inhibited neurotransmitter release, no descending excitation would remain, no locomotion would occur, and other spinal modulatory effects of 5-HT would be moot in behaving vertebrates.

$\text{G}\beta\gamma$ SNARE complex interactions also allow for the possibility of differentially modulating evoked and spontaneous release of neurotransmitter. This mechanism of modulation does not significantly alter spontaneous release of glutamate in the hippocampal CA1-subiculum [32], nor in lamprey spinal cord [136]. However, it does in Chromaffin cells [137]. Differences in SNARE complex proteins [138–140] or possible Ca^{2+} sensors [81, 141] utilized for these different fusion mechanisms might account for these various effects of GPCRs.

For the future, it is clear that the mechanisms by which $\text{G}\beta\gamma$ targeting of SNARE complexes leads to modification of the mode of synaptic vesicle fusion causing kiss-and-run fusion are important across a range of systems that require SNARE-dependent vesicle fusion. Thus, in central synapses this mode of fusion both allows selective inhibition of particular postsynaptic receptors [142, 143], but also a large dynamic range of presynaptic inhibition, while in endocrine large dense core fusion events, this mode may allow for selective release of neurotransmitters within or surrounding the dense core matrix [144, 145]. We have demonstrated the interaction between synaptotagmin1, $\text{G}\beta\gamma$ and the SNARE complex. Nevertheless, competition between $\text{G}\beta\gamma$ and syt1 – the tagmin responsible for evoked release – at SNARE complexes is unlikely to account for the loss of $\text{G}\beta\gamma$ -SNARE interaction during trains (Fig 1) because the high $[\text{Ca}^{2+}]$ that allows Ca^{2+} -syt1 binding, does not sufficiently sum. It seems more likely that presynaptic modulation requires multiple fusogenic Ca^{2+} sensors which differentially interact with different $\text{G}\beta\gamma$ modulators. Possible candidate C2AB domain containing proteins have been implicated in the modulation of fusion during stimulus trains. These include synaptotagmin 7 [83] and Doc2a

and β [146, 147], and warrant further investigation. Finally, the $G\beta\gamma$ -SNARE interaction and its modulation of exocytosis downstream of presynaptic calcium entry is an important neuromodulatory mechanism in a large diversity of circuits, mediating multiple physiologic behaviors. Future studies should focus on identifying the $G_{i/o}$ -coupled GPCRs that signal via $G\beta\gamma$ -SNARE.

Acknowledgments

We would like to thank Dr Ed Chapman, University of Wisconsin, Madison for advice on liposomal fusion, and Dr Réjean Dubuc, Université de Montréal for advice on brainstem evoked locomotor behavior. Funding was provided by the following R01 grants NIH (NIMH) R01MH101679 to Heidi Hamm and R01MH084874 to Simon Alford.

References

1. Miller RJ. 1998; Presynaptic receptors. Annual review of pharmacology and toxicology. 38:201–227. DOI: 10.1146/annurev.pharmtox.38.1.201
2. Eccles JC, Schmidt RF, Willis WD. 1963; Pharmacological studies on presynaptic inhibition. JPhysiol. 168:500–530. [PubMed: 14067941]
3. Alger BE, Nicoll RA. 1979; GABA-mediated biphasic inhibitory responses in hippocampus. Nature. 281:315–317. [PubMed: 551280]
4. Starke K. 1972; Influence of extracellular noradrenaline on the stimulation-evoked secretion of noradrenaline from sympathetic nerves: evidence for an α -receptor-mediated feed-back inhibition of noradrenaline release. Naunyn-Schmiedeberg's Archiv für Pharmakologie. 275:11–23.
5. Dutar P, Nicoll RA. 1988; Pre- and postsynaptic GABAB receptors in the hippocampus have different pharmacological properties. Neuron. 1:585–591. [PubMed: 2856099]
6. Cochilla AJ, Alford S. 1998; Metabotropic glutamate receptor-mediated control of neurotransmitter release. Neuron. 20:1007–1016. [PubMed: 9620704]
7. Blackmer T, Larsen EC, Takahashi M, et al. 2001; G protein betagamma subunit-mediated presynaptic inhibition: regulation of exocytotic fusion downstream of Ca^{2+} entry. Science. 292:293–297. DOI: 10.1126/science.1058803 [PubMed: 11303105]
8. Eccles JC, Schmidt RF, Willis WD. 1963; The mode of operation of synaptic mechanisms producing presynaptic inhibition. J Neurophysiol. 26:523–538.
9. Alford S, Grillner S. 1991; The involvement of GABAB receptors and coupled G-proteins in spinal GABAergic presynaptic inhibition. J Neurosci. 11:3718–3726. [PubMed: 1660534]
10. Brodin L, Buchanan JT, Hökfelt T, et al. 1986; A spinal projection of 5-hydroxytryptamine neurons in the lamprey brainstem; evidence from combined retrograde tracing and immunohistochemistry. Neurosci Lett. 67:53–57. [PubMed: 3725200]
11. Tyler EC, Lovinger DM. 1995; Metabotropic glutamate receptor modulation of synaptic transmission in corticostriatal co-cultures: role of calcium influx. Neuropharmacology. 34:939–952. [PubMed: 8532175]
12. Davies CH, Collingridge GL. 1996; Regulation of EPSPs by the synaptic activation of GABAB autoreceptors in rat hippocampus. J Physiol (Lond). 496(Pt 2):451–470. [PubMed: 8910229]
13. Chittajallu R, Vignes M, Dev KK, et al. 1996; Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature. 379:78–81. DOI: 10.1038/379078a0 [PubMed: 8538745]
14. Emptage NJ, Reid CA, Fine A, Bliss TVP. 2003; Optical quantal analysis reveals a presynaptic component of LTP at hippocampal Schaffer-associational synapses. Neuron. 38:797–804. [PubMed: 12797963]
15. Dunlap K, Fischbach GD. 1978; Neurotransmitters decrease the calcium component of sensory neurone action potentials. Nature. 276:837–839. [PubMed: 31570]
16. Holz GGT, Kream RM, Spiegel A, Dunlap K. 1989; G proteins couple α -adrenergic and GABAB receptors to inhibition of peptide secretion from peripheral sensory neurons. J Neurosci. 9:657–666. [PubMed: 2465394]

17. Clapham DE, Neer EJ. 1997; G protein beta gamma subunits. Annual review of pharmacology and toxicology. 37:167–203.
18. Wu LG, Saggau P. 1995; GABAB receptor-mediated presynaptic inhibition in guinea-pig hippocampus is caused by reduction of presynaptic Ca²⁺ influx. J Physiol (Lond). 485(Pt 3):649–657. [PubMed: 7562607]
19. Silinsky EM. 1984; On the mechanism by which adenosine receptor activation inhibits the release of acetylcholine from motor nerve endings. J Physiol (Lond). 346:243–256. [PubMed: 6321717]
20. Silinsky EM, Hunt JM, Solsona CS, Hirsh JK. 1990; Prejunctional adenosine and ATP receptors. Ann N Y Acad Sci. 603:324–333. [PubMed: 1963282]
21. Dolphin AC, Scott RH. 1987; Calcium channel currents and their inhibition by (–)-baclofen in rat sensory neurones: modulation by guanine nucleotides. J Physiol (Lond). 386:1–17. [PubMed: 2445960]
22. Shapiro MS, Hille B. 1993; Substance P and somatostatin inhibit calcium channels in rat sympathetic neurons via different G protein pathways. Neuron. 10:11–20. [PubMed: 7678964]
23. Delaney AJ, Crane JW, Sah P. 2007; Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron. 56:880–892. [PubMed: 18054863]
24. Trombley PQ, Westbrook GL. 1992; L-AP4 inhibits calcium currents and synaptic transmission via a G-protein-coupled glutamate receptor. J Neurosci. 12:2043–2050. [PubMed: 1318954]
25. Bourinet E, et al. 1996; Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci USA. 93:1486–1491. [PubMed: 8643659]
26. Mizuno T, Schmauss C, Rayport S. 2007; Distinct roles of presynaptic dopamine receptors in the differential modulation of the intrinsic synapses of medium-spiny neurons in the nucleus accumbens. BMC Neurosci. 8:8.doi: 10.1186/1471-2202-8-8 [PubMed: 17239247]
27. Ford CE, Skiba NP, Bae H, et al. 1998; Molecular basis for interactions of G protein betagamma subunits with effectors. Science. 280:1271–1274. [PubMed: 9596582]
28. Dolphin AC, Pearson HA, Menon-Johansson AS, et al. 1993; G protein modulation of voltage-dependent calcium channels and transmitter release. Biochem Soc Trans. 21:391–395. [PubMed: 8103002]
29. Toth PT, et al. 1996; Selective G-protein regulation of neuronal calcium channels. J Neurosci. 16:4617–4624. [PubMed: 8764650]
30. De Waard M, Liu H, Walker D, et al. 1997; Direct binding of G-protein betagamma complex to voltage-dependent calcium channels. Nature. 385:446–450. [PubMed: 9009193]
31. Qin N, Platano D, Olcese R, et al. 1997; Direct interaction of gbetagamma with a C-terminal gbetagamma-binding domain of the Ca²⁺ channel alpha1 subunit is responsible for channel inhibition by G protein-coupled receptors. Proc Natl Acad Sci USA. 94:8866–8871. [PubMed: 9238069]
32. Hamid E, Wells CA, Zurawski Z, et al. 2014; Modulation of neurotransmission by GPCRs is dependent upon the microarchitecture of the primed vesicle complex. J Neurosci. 34:260–274. DOI: 10.1523/JNEUROSCI.3633-12.2014 [PubMed: 24381287]
33. Mizutani H, Hori T, Takahashi T. 2006; 5-HT_{1B} receptor-mediated presynaptic inhibition at the calyx of Held of immature rats. Eur J Neurosci. 24:1946–1954. DOI: 10.1111/j.1460-9568.2006.05063.x [PubMed: 17067296]
34. Logothetis DE, Kurachi Y, Galper J, et al. 1987; The beta gamma subunits of GTP-binding proteins activate the muscarinic K⁺ channel in heart. Nature. 325:321–326. [PubMed: 2433589]
35. Reuveny E, Slesinger PA, Inglese J, et al. 1994; Activation of the cloned muscarinic potassium channel by G protein beta gamma subunits. Nature. 370:143–146. DOI: 10.1038/370143a0 [PubMed: 8022483]
36. Huang CL, Slesinger PA, Casey PJ, et al. 1995; Evidence that direct binding of G beta gamma to the GIRK1 G protein-gated inwardly rectifying K⁺ channel is important for channel activation. Neuron. 15:1133–1143. [PubMed: 7576656]
37. Michaeli A, Yaka R. 2010; Dopamine inhibits GABA(A) currents in ventral tegmental area dopamine neurons via activation of presynaptic G-protein coupled inwardly-rectifying potassium channels. Neuroscience. 165:1159–1169. DOI: 10.1016/j.neuroscience.2009.11.045 [PubMed: 19944748]

38. Ma JY, Li M, Catterall WA, Scheuer T. 1994; Modulation of brain Na⁺ channels by a G-protein-coupled pathway. *Proc Natl Acad Sci USA*. 91:12351–12355. [PubMed: 7991631]
39. Kowluru A, Seavey SE, Rhodes CJ, Metz SA. 1996; A novel regulatory mechanism for trimeric GTP-binding proteins in the membrane and secretory granule fractions of human and rodent beta cells. *Biochem J*. 313:97–107. [PubMed: 8546716]
40. Pinxteren JA, O'Sullivan AJ, Tatham PE, Gomperts BD. 1998; Regulation of exocytosis from rat peritoneal mast cells by G protein beta gamma-subunits. *EMBO J*. 17:6210–6218. DOI: 10.1093/emboj/17.21.6210 [PubMed: 9799230]
41. Lang J. 1999; Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion. *Eur J Biochem*. 259:3–17. [PubMed: 9914469]
42. Silinsky EM, Solsona CS. 1992; Calcium currents at motor nerve endings: absence of effects of adenosine receptor agonists in the frog. *J Physiol (Lond)*. 457:315–328. [PubMed: 1338459]
43. Scholz KP, Miller RJ. 1992; Inhibition of quantal transmitter release in the absence of calcium influx by a G protein-linked adenosine receptor at hippocampal synapses. *Neuron*. 8:1139–1150. [PubMed: 1351733]
44. Gereau RWT, Conn PJ. 1995; Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. *J Neurosci*. 15:6879–6889. [PubMed: 7472445]
45. Scanziani M, Gähwiler BH, Thompson SM. 1995; Presynaptic inhibition of excitatory synaptic transmission by muscarinic and metabotropic glutamate receptor activation in the hippocampus: are Ca²⁺ channels involved? *Neuropharmacology*. 34:1549–1557. [PubMed: 8606802]
46. Umemiya M, Berger AJ. 1995; Presynaptic inhibition by serotonin of glycinergic inhibitory synaptic currents in the rat brain stem. *J Neurophysiol*. 73:1192–1201. [PubMed: 7608765]
47. Luini A, De Matteis MA. 1990; Evidence that receptor-linked G protein inhibits exocytosis by a post- second-messenger mechanism in AtT-20 cells. *J Neurochem*. 54:30–38. [PubMed: 1967144]
48. Blackmer T, Larsen EC, Bartleson C, et al. 2005; G protein betagamma directly regulates SNARE protein fusion machinery for secretory granule exocytosis. *Nat Neurosci*. 8:421–425. DOI: 10.1038/nn1423 [PubMed: 15778713]
49. Blackmer T, Larsen EC, Bartleson C, et al. 2005; G protein betagamma directly regulates SNARE protein fusion machinery for secretory granule exocytosis. *Nat Neurosci*. 8:421–425. DOI: 10.1038/nn1423 [PubMed: 15778713]
50. Melzack R, Wall PD. 1965; Pain mechanisms: a new theory. *Science*. 150:971–979. [PubMed: 5320816]
51. Price GW, Wilkin GP, Turnbull MJ, Bowery NG. 1984; Are baclofen-sensitive GABAB receptors present on primary afferent terminals of the spinal cord? *Nature*. 307:71–74. [PubMed: 6318120]
52. Buchanan JT, Grillner S. 1991; 5-hydroxytryptamine depresses reticulospinal excitatory post synaptic potentials in motoneurons of the lamprey. *NeurosciLett*. 122:71–74.
53. Celada P, Puig MV, Artigas F. 2013; Serotonin modulation of cortical neurons and networks. *Front Integr Neurosci*. 7:25.doi: 10.3389/fnint.2013.00025 [PubMed: 23626526]
54. Dugladze T, Maziashvili N, Börgers C, et al. 2013; GABA(B) autoreceptor-mediated cell type-specific reduction of inhibition in epileptic mice. *Proc Natl Acad Sci USA*. 110:15073–15078. DOI: 10.1073/pnas.1313505110 [PubMed: 23980149]
55. Dobrunz LE, Huang EP, Stevens CF. 1997; Very short-term plasticity in hippocampal synapses. *Proc Natl Acad Sci USA*. 94:14843–14847. [PubMed: 9405701]
56. Ma C, Li W, Xu Y, Rizo J. 2011; Munc13 mediates the transition from the closed syntaxin-Munc18 complex to the SNARE complex. *Nature structural & molecular biology*. 18:542–549. DOI: 10.1038/nsmb.2047
57. Tang A-H, Chen H, Li TP, et al. 2016; A trans-synaptic nanocolumn aligns neurotransmitter release to receptors. *Nature*. 536:210–214. DOI: 10.1038/nature19058 [PubMed: 27462810]
58. Zhang Q, Li Y, Tsien RW. 2009; The dynamic control of kiss-and-run and vesicular reuse probed with single nanoparticles. *Science*. 323:1448–1453. DOI: 10.1126/science.1167373 [PubMed: 19213879]

59. Photowala H, Blackmer T, Schwartz E, et al. 2006; G protein betagamma-subunits activated by serotonin mediate presynaptic inhibition by regulating vesicle fusion properties. *Proc Natl Acad Sci USA*. 103:4281–4286. DOI: 10.1073/pnas.0600509103 [PubMed: 16537522]
60. Betke KM, Wells CA, Hamm HE. 2012; GPCR mediated regulation of synaptic transmission. *Prog Neurobiol*. 96:304–321. DOI: 10.1016/j.pneurobio.2012.01.009 [PubMed: 22307060]
61. Brown DA, Sihra TS. 2008; Presynaptic signaling by heterotrimeric G-proteins. *Handb Exp Pharmacol*. :207–260. DOI: 10.1007/978-3-540-74805-2_8 [PubMed: 18064416]
62. Schmitz D, Frerking M, Nicoll RA. 2000; Synaptic activation of presynaptic kainate receptors on hippocampal mossy fiber synapses. *Neuron*. 27:327–338. [PubMed: 10985352]
63. Alford S, Christenson J, Grillner S. 1991; Presynaptic GABAA and GABAB Receptor-mediated Phasic Modulation in Axons of Spinal Motor Interneurons. *Eur J Neurosci*. 3:107–117. [PubMed: 12106209]
64. Jahn R, Scheller RH. 2006; SNAREs--engines for membrane fusion. *Nat Rev Mol Cell Biol*. 7:631–643. DOI: 10.1038/nrm2002 [PubMed: 16912714]
65. Sutton RB, Fasshauer D, Jahn R, Brunger AT. 1998; Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 Å resolution. *Nature*. 395:347–353. DOI: 10.1038/26412 [PubMed: 9759724]
66. Augustine GJ, Adler EM, Charlton MP. 1991; The Calcium Signal for Transmitter Secretion from Presynaptic Nerve Terminals - AUGUSTINE-- 2006 - *Annals of the New York Academy of Sciences - Wiley Online Library*. Ann N Y Acad Sci. 635:365–381. [PubMed: 1683754]
67. Geppert M, Goda Y, Hammer RE, et al. 1994; Synaptotagmin I: a major Ca²⁺ sensor for transmitter release at a central synapse. *Cell*. 79:717–727. [PubMed: 7954835]
68. Chapman ER. 2002; Synaptotagmin: a Ca²⁺ sensor that triggers exocytosis? *Nat Rev Mol Cell Biol*. 3:498–508. DOI: 10.1038/nrm855 [PubMed: 12094216]
69. Dresbach T, Burns ME, O'Connor V, et al. 1998; A neuronal Sec1 homolog regulates neurotransmitter release at the squid giant synapse. *J Neurosci*. 18:2923–2932. [PubMed: 9526009]
70. Rizo J, Xu J. 2015; The Synaptic Vesicle Release Machinery. *Annu Rev Biophys*. 44:339–367. DOI: 10.1146/annurev-biophys-060414-034057 [PubMed: 26098518]
71. Richmond JE, Davis WS, Jorgensen EM. 1999; UNC-13 is required for synaptic vesicle fusion in *C. elegans*. *Nat Neurosci*. 2:959–964. DOI: 10.1038/14755 [PubMed: 10526333]
72. Yang X, Wang S, Sheng Y, et al. 2015; Syntaxin opening by the MUN domain underlies the function of Munc13 in synaptic-vesicle priming. *Nature structural & molecular biology*. 22:547–554. DOI: 10.1038/nsmb.3038
73. Yang X, Cao P, Südhof TC. 2013; Deconstructing complexin function in activating and clamping Ca²⁺-triggered exocytosis by comparing knockout and knockdown phenotypes. *Proc Natl Acad Sci USA*. 110:20777–20782. DOI: 10.1073/pnas.1321367110 [PubMed: 24297916]
74. Deák F, Shin O-H, Tang J, et al. 2006; Rabphilin regulates SNARE-dependent re-priming of synaptic vesicles for fusion. *EMBO J*. 25:2856–2866. DOI: 10.1038/sj.emboj.7601165 [PubMed: 16763567]
75. Schlüter OM, Basu J, Südhof TC, Rosenmund C. 2006; Rab3 superprimes synaptic vesicles for release: implications for short-term synaptic plasticity. *J Neurosci*. 26:1239–1246. DOI: 10.1523/JNEUROSCI.3553-05.2006 [PubMed: 16436611]
76. Stanley EF, Mirotznik RR. 1997; Cleavage of syntaxin prevents G-protein regulation of presynaptic calcium channels. *Nature*. 385:340–343. [PubMed: 9002518]
77. Yoon E-J, Gerachshenko T, Spiegelberg BD, et al. 2007; Gbetagamma interferes with Ca²⁺-dependent binding of synaptotagmin to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex. *Mol Pharmacol*. 72:1210–1219. DOI: 10.1124/mol.107.039446 [PubMed: 17715396]
78. Catterall WA, Few AP. 2008; Calcium channel regulation and presynaptic plasticity. *Neuron*. 59:882–901. DOI: 10.1016/j.neuron.2008.09.005 [PubMed: 18817729]
79. Chapman ER, Jahn R. 1994; Calcium-dependent interaction of the cytoplasmic region of synaptotagmin with membranes. Autonomous function of a single C2-homologous domain. *The Journal of biological chemistry*. 269:5735–5741. [PubMed: 8119912]

80. Perin MS, Brose N, Jahn R, Südhof TC. 1991; Domain structure of synaptotagmin (p65). *The Journal of biological chemistry*. 266:623–629. [PubMed: 1985919]
81. Yao J, Gaffaney JD, Kwon SE, Chapman ER. 2011; Doc2 is a Ca²⁺ sensor required for asynchronous neurotransmitter release. *Cell*. 147:666–677. DOI: 10.1016/j.cell.2011.09.046 [PubMed: 22036572]
82. Weber JP, Toft-Bertelsen TL, Mohrmann R, et al. 2014; Synaptotagmin-7 is an asynchronous calcium sensor for synaptic transmission in neurons expressing SNAP-23. *PLoS ONE*. 9:e114033.doi: 10.1371/journal.pone.0114033 [PubMed: 25422940]
83. Jackman SL, Turecek J, Belinsky JE, Regehr WG. 2016; The calcium sensor synaptotagmin 7 is required for synaptic facilitation. *Nature*. 529:88–91. DOI: 10.1038/nature16507 [PubMed: 26738595]
84. Südhof TC. 2002; Synaptotagmins: why so many? *The Journal of biological chemistry*. 277:7629–7632. DOI: 10.1074/jbc.R100052200 [PubMed: 11739399]
85. Zhou Q, Lai Y, Bacaj T, et al. 2015; Architecture of the synaptotagmin-SNARE machinery for neuronal exocytosis. *Nature*. 525:62–67. DOI: 10.1038/nature14975 [PubMed: 26280336]
86. Sugita S, Shin O-H, Han W, et al. 2002; Synaptotagmins form a hierarchy of exocytotic Ca(2+) sensors with distinct Ca(2+) affinities. *EMBO J*. 21:270–280. DOI: 10.1093/emboj/21.3.270 [PubMed: 11823420]
87. Chapman ER, Hanson PI, An S, Jahn R. 1995; Ca²⁺ regulates the interaction between synaptotagmin and syntaxin 1. *The Journal of biological chemistry*. 270:23667–23671. [PubMed: 7559535]
88. Zhang X, Kim-Miller MJ, Fukuda M, et al. 2002; Ca²⁺-dependent synaptotagmin binding to SNAP-25 is essential for Ca²⁺-triggered exocytosis. *Neuron*. 34:599–611. [PubMed: 12062043]
89. Gerona RR, Larsen EC, Kowalchuk JA, Martin TF. 2000; The C terminus of SNAP25 is essential for Ca(2+)-dependent binding of synaptotagmin to SNARE complexes. *The Journal of biological chemistry*. 275:6328–6336. [PubMed: 10692432]
90. Liu H, Bai H, Xue R, et al. 2014; Linker mutations reveal the complexity of synaptotagmin 1 action during synaptic transmission. *Nat Neurosci*. 17:670–677. DOI: 10.1038/nn.3681 [PubMed: 24657966]
91. Bai H, Xue R, Bao H, et al. 2016; Different states of synaptotagmin regulate evoked versus spontaneous release. *Nat Commun*. 7:10971.doi: 10.1038/ncomms10971 [PubMed: 27001899]
92. Bailey CP, Nicholls RE, Zhang X-L, et al. 2008; Gα(i2) inhibition of adenylate cyclase regulates presynaptic activity and unmasks cGMP-dependent long-term depression at Schaffer collateral-CA1 hippocampal synapses. *Learn Mem*. 15:261–270. DOI: 10.1101/lm.810208 [PubMed: 18391187]
93. Chen K, Richlitzki A, Featherstone DE, et al. 2011; Tomosyn-dependent regulation of synaptic transmission is required for a late phase of associative odor memory. *Proc Natl Acad Sci USA*. 108:18482–18487. DOI: 10.1073/pnas.1110184108 [PubMed: 22042858]
94. Cho RW, Buhl LK, Volfson D, et al. 2015; Phosphorylation of Complexin by PKA Regulates Activity-Dependent Spontaneous Neurotransmitter Release and Structural Synaptic Plasticity. *Neuron*. 88:749–761. DOI: 10.1016/j.neuron.2015.10.011 [PubMed: 26590346]
95. Zhang X-L, Upreti C, Stanton PK. 2011; Gβγ and the C terminus of SNAP-25 are necessary for long-term depression of transmitter release. *PLoS ONE*. 6:e20500.doi: 10.1371/journal.pone.0020500 [PubMed: 21633701]
96. Upreti C, Zhang X-L, Alford S, Stanton PK. 2013; Role of presynaptic metabotropic glutamate receptors in the induction of long-term synaptic plasticity of vesicular release. *Neuropharmacology*. 66:31–39. DOI: 10.1016/j.neuropharm.2012.05.004 [PubMed: 22626985]
97. Takahashi M, Freed R, Blackmer T, Alford S. 2001; Calcium influx-independent depression of transmitter release by 5-HT at lamprey spinal cord synapses. *J Physiol (Lond)*. 532:323–336. [PubMed: 11306653]
98. Gerachshenko T, Blackmer T, Yoon E-J, et al. 2005; Gbetagamma acts at the C terminus of SNAP-25 to mediate presynaptic inhibition. *Nat Neurosci*. 8:597–605. DOI: 10.1038/nn1439 [PubMed: 15834421]

99. Schwartz EJ, Gerachshenko T, Alford S. 2005; 5-HT prolongs ventral root bursting via presynaptic inhibition of synaptic activity during fictive locomotion in lamprey. *J Neurophysiol.* 93:980–988. DOI: 10.1152/jn.00669.2004 [PubMed: 15456802]
100. Pellegrini LL, O'Connor V, Betz H. 1994; Fusion complex formation protects synaptobrevin against proteolysis by tetanus toxin light chain. *FEBS Lett.* 353:319–323. [PubMed: 7957884]
101. Chen X-K, Wang L-C, Zhou Y, et al. 2005; Activation of GPCRs modulates quantal size in chromaffin cells through G(betagamma) and PKC. *Nat Neurosci.* 8:1160–1168. DOI: 10.1038/nn1529 [PubMed: 16116443]
102. Wells CA, Zurawski Z, Betke KM, et al. 2012; Gβγ inhibits exocytosis via interaction with critical residues on soluble N-ethylmaleimide-sensitive factor attachment protein-25. *Mol Pharmacol.* 82:1136–1149. DOI: 10.1124/mol.112.080507 [PubMed: 22962332]
103. Wells CA, Zurawski Z, Betke KM, et al. 2012; Gβγ inhibits exocytosis via interaction with critical residues on soluble N-ethylmaleimide-sensitive factor attachment protein-25. *Mol Pharmacol.* 82:1136–1149. DOI: 10.1124/mol.112.080507 [PubMed: 22962332]
104. Weber T, Zemelman BV, McNew JA, et al. 1998; SNAREpins: minimal machinery for membrane fusion. *Cell.* 92:759–772. [PubMed: 9529252]
105. Tucker WC, Weber T, Chapman ER. 2004; Reconstitution of Ca²⁺-regulated membrane fusion by synaptotagmin and SNAREs. *Science.* 304:435–438. DOI: 10.1126/science.1097196 [PubMed: 15044754]
106. Bhalla A, Chicka MC, Tucker WC, Chapman ER. 2006; Ca(2+)-synaptotagmin directly regulates t-SNARE function during reconstituted membrane fusion. *Nature structural & molecular biology.* 13:323–330. DOI: 10.1038/nsmb1076
107. Gaffaney JD, Dunning FM, Wang Z, et al. 2008; Synaptotagmin C2B domain regulates Ca²⁺-triggered fusion in vitro: critical residues revealed by scanning alanine mutagenesis. *The Journal of biological chemistry.* 283:31763–31775. DOI: 10.1074/jbc.M803355200 [PubMed: 18784080]
108. Gerachshenko T, Schwartz E, Bleckert A, et al. 2009; Presynaptic G-protein-coupled receptors dynamically modify vesicle fusion, synaptic cleft glutamate concentrations, and motor behavior. *J Neurosci.* 29:10221–10233. DOI: 10.1523/JNEUROSCI.1404-09.2009 [PubMed: 19692597]
109. Schwartz EJ, Blackmer T, Gerachshenko T, Alford S. 2007; Presynaptic G-protein-coupled receptors regulate synaptic cleft glutamate via transient vesicle fusion. *J Neurosci.* 27:5857–5868. DOI: 10.1523/JNEUROSCI.1160-07.2007 [PubMed: 17537956]
110. Kay AR, Alfonso A, Alford S, et al. 1999; Imaging synaptic activity in intact brain and slices with FM1-43 in *C. elegans*, lamprey, and rat. *Neuron.* 24:809–817. [PubMed: 10624945]
111. Richards DA, Bai J, Chapman ER. 2005; Two modes of exocytosis at hippocampal synapses revealed by rate of FM1-43 efflux from individual vesicles. *The Journal of cell biology.* 168:929–939. DOI: 10.1083/jcb.200407148 [PubMed: 15767463]
112. Clements JD, Lester RA, Tong G, et al. 1992; The time course of glutamate in the synaptic cleft. *Science.* 258:1498–1501. [PubMed: 1359647]
113. Diamond JS, Bergles DE, Jahr CE. 1998; Glutamate release monitored with astrocyte transporter currents during LTP. *Neuron.* 21:425–433. [PubMed: 9728923]
114. Alabi AA, Tsien RW. 2013; Perspectives on kiss-and-run: role in exocytosis, endocytosis, and neurotransmission. *Annu Rev Physiol.* 75:393–422. DOI: 10.1146/annurev-physiol-020911-153305 [PubMed: 23245563]
115. Choi S, Klingauf J, Tsien RW. 2000; Postfusional regulation of cleft glutamate concentration during LTP at 'silent synapses'. *Nat Neurosci.* 3:330–336. DOI: 10.1038/73895 [PubMed: 10725921]
116. Grillner S. 2006; Biological pattern generation: the cellular and computational logic of networks in motion. *Neuron.* 52:751–766. DOI: 10.1016/j.neuron.2006.11.008 [PubMed: 17145498]
117. Brodin L, Grillner S, Rovainen CM. 1985; N-Methyl-D-aspartate (NMDA), kainate and quisqualate receptors and the generation of fictive locomotion in the lamprey spinal cord. *Brain Res.* 325:302–306. [PubMed: 2858251]
118. Brodin L, Grillner S. 1986; Effects of magnesium on fictive locomotion induced by activation of N-methyl-D-aspartate (NMDA) receptors in the lamprey spinal cord in vitro. *Brain Res.* 380:244–252. [PubMed: 2428424]

119. Wallén P, Grillner S. 1987; N-methyl-D-aspartate receptor-induced, inherent oscillatory activity in neurons active during fictive locomotion in the lamprey. *J Neurosci.* 7:2745–2755. [PubMed: 3040925]
120. Parker D, Grillner S. 1999; Activity-dependent metaplasticity of inhibitory and excitatory synaptic transmission in the lamprey spinal cord locomotor network. *J Neurosci.* 19:1647–1656. [PubMed: 10024351]
121. Parker D, Grillner S. 1998; Cellular and synaptic modulation underlying substance P-mediated plasticity of the lamprey locomotor network. *J Neurosci.* 18:8095–8110. [PubMed: 9742176]
122. Dubuc R, Brocard F, Antri M, et al. 2008; Initiation of locomotion in lampreys. *Brain Res Rev.* 57:172–182. [PubMed: 17916380]
123. Brodin L, Tråvén HG, Lansner A, et al. 1991; Computer simulations of N-methyl-D-aspartate receptor-induced membrane properties in a neuron model. *J Neurophysiol.* 66:473–484. [PubMed: 1723094]
124. Harris-Warrick RM, Cohen AH. 1985; Serotonin modulates the central pattern generator for locomotion in the isolated lamprey spinal cord. *J Exp Biol.* 116:27–46. [PubMed: 4056654]
125. Wang D, Grillner S, Wallén P. 2011; 5-HT and dopamine modulates CaV1.3 calcium channels involved in postinhibitory rebound in the spinal network for locomotion in lamprey. *J Neurophysiol.* 105:1212–1224. DOI: 10.1152/jn.00324.2009 [PubMed: 21228305]
126. Di Prisco GV, Dubuc R, Wallén P, Grillner S. 1992; 5-Hydroxytryptamine modulates spike frequency regulation in reticulospinal neurons involved in the control of locomotion in lamprey. *Neurosci Lett.* 134:279–283. [PubMed: 1589154]
127. Wallén P, Buchanan JT, Grillner S, et al. 1989; Effects of 5-hydroxytryptamine on the afterhyperpolarization, spike frequency regulation, and oscillatory membrane properties in lamprey spinal cord neurons. *J Neurophysiol.* 61:759–768. [PubMed: 2542472]
128. Tråvén HG, Brodin L, Lansner A, et al. 1993; Computer simulations of NMDA and non-NMDA receptor-mediated synaptic drive: sensory and supraspinal modulation of neurons and small networks. *J Neurophysiol.* 70:695–709. [PubMed: 8105036]
129. Del Castillo J, Katz B. 1954; Quantal components of the end-plate potential. *J Physiol (Lond).* 124:560–573. [PubMed: 13175199]
130. Katz B. 1971; Quantal mechanism of neural transmitter release. *Science.* 173:123–6. [PubMed: 4325812]
131. Ceccarelli B, Hurlbut WP, Mauro A. 1973; Turnover of transmitter and synaptic vesicles at the frog neuromuscular junction. *The Journal of cell biology.* 57:499–524. [PubMed: 4348791]
132. Harata NC, Aravanis AM, Tsien RW. 2006; Kiss-and-run and full-collapse fusion as modes of exo-endocytosis in neurosecretion. *J Neurochem.* 97:1546–1570. DOI: 10.1111/j.1471-4159.2006.03987.x [PubMed: 16805768]
133. Yoon E-J, Hamm HE, Currie KPM. 2008; G protein betagamma subunits modulate the number and nature of exocytotic fusion events in adrenal chromaffin cells independent of calcium entry. *J Neurophysiol.* 100:2929–2939. DOI: 10.1152/jn.90839.2008 [PubMed: 18815342]
134. Perrier J-F, Cotel F. 2015; Serotonergic modulation of spinal motor control. *Curr Opin Neurobiol.* 33:1–7. DOI: 10.1016/j.conb.2014.12.008 [PubMed: 25553359]
135. Madriaga MA, McPhee LC, Chersa T, et al. 2004; Modulation of locomotor activity by multiple 5-HT and dopaminergic receptor subtypes in the neonatal mouse spinal cord. *J Neurophysiol.* 92:1566–1576. DOI: 10.1152/jn.01181.2003 [PubMed: 15163678]
136. Takahashi M, Freed R, Blackmer T, Alford S. 2001; Calcium influx-independent depression of transmitter release by 5-HT at lamprey spinal cord synapses. *J Physiol (Lond).* 532:323–336. [PubMed: 11306653]
137. Yoon E-J, Hamm HE, Currie KPM. 2008; G protein betagamma subunits modulate the number and nature of exocytotic fusion events in adrenal chromaffin cells independent of calcium entry. *J Neurophysiol.* 100:2929–2939. DOI: 10.1152/jn.90839.2008 [PubMed: 18815342]
138. Daraio T, Valladolí-Acebes I, Brismar K, Bark C. 2018; SNAP-25a and SNAP-25b differently mediate interactions with Munc18-1 and Gβγ subunits. *Neurosci Lett.* 674:75–80. DOI: 10.1016/j.neulet.2018.03.024 [PubMed: 29548989]

139. Kavalali ET, Chung C, Khvotchev M, et al. 2011; Spontaneous neurotransmission: an independent pathway for neuronal signaling? *Physiology (Bethesda)*. 26:45–53. DOI: 10.1152/physiol.00040.2010 [PubMed: 21357902]
140. Ramirez DMO, Kavalali ET. 2012; The role of non-canonical SNAREs in synaptic vesicle recycling. *Cell Logist.* 2:20–27. DOI: 10.4161/cl.20114 [PubMed: 22645707]
141. Bacaj T, Wu D, Yang X, et al. 2013; Synaptotagmin-1 and synaptotagmin-7 trigger synchronous and asynchronous phases of neurotransmitter release. *Neuron*. 80:947–959. DOI: 10.1016/j.neuron.2013.10.026 [PubMed: 24267651]
142. Gerachshenko T, Schwartz E, Bleckert A, et al. 2009; Presynaptic G-protein-coupled receptors dynamically modify vesicle fusion, synaptic cleft glutamate concentrations, and motor behavior. *J Neurosci.* 29:10221–10233. DOI: 10.1523/JNEUROSCI.1404-09.2009 [PubMed: 19692597]
143. Schwartz EJ, Blackmer T, Gerachshenko T, Alford S. 2007; Presynaptic G-protein-coupled receptors regulate synaptic cleft glutamate via transient vesicle fusion. *J Neurosci.* 27:5857–5868. DOI: 10.1523/JNEUROSCI.1160-07.2007 [PubMed: 17537956]
144. Rahamimoff R, Fernandez JM. 1997; Pre- and postfusion regulation of transmitter release. *Neuron*. 18:17–27. [PubMed: 9010202]
145. Angleson JK, Cochilla AJ, Kilic G, et al. 1999; Regulation of dense core release from neuroendocrine cells revealed by imaging single exocytic events. *Nat Neurosci.* 2:440–446. DOI: 10.1038/8107 [PubMed: 10321248]
146. Groffen AJA, Friedrich R, Brian EC, et al. 2006; DOC2A and DOC2B are sensors for neuronal activity with unique calcium-dependent and kinetic properties. *J Neurochem.* 97:818–833. DOI: 10.1111/j.1471-4159.2006.03755.x [PubMed: 16515538]
147. Yao J, Gaffaney JD, Kwon SE, Chapman ER. 2011; Doc2 is a Ca²⁺ sensor required for asynchronous neurotransmitter release. *Cell*. 147:666–677. DOI: 10.1016/j.cell.2011.09.046 [PubMed: 22036572]
148. Sutton RB, Fasshauer D, Jahn R, Brunger AT. 1998; Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 Å resolution. *Nature*. 395:347–353. DOI: 10.1038/26412 [PubMed: 9759724]

Figure 1. Schematic showing 3 possible mechanisms by which G protein $\text{Ca}_{i/o}$ -dependent presynaptic inhibition is mediated by $\text{G}\beta\gamma$

A) $\text{G}\beta\gamma$ (blue) inhibits presynaptic Ca^{2+} entry, shortening the action potential, reducing the Ca^{2+} transient and inhibiting the EPSC.

B) $\text{G}\beta\gamma$ activates a presynaptic GIRK channels, reducing action potential amplitude and subsequently presynaptic Ca^{2+} entry and the resultant EPSC.

C) $\text{G}\beta\gamma$ directly targets the SNARE complex in the presynaptic terminal, giving no effect on the presynaptic action potential, or Ca^{2+} entry, but still inhibiting the EPSC.

Figure 2. Paired cell recordings between lamprey giant axons and their postsynaptic targets reveal a Gβγ-dependent mechanism of presynaptic inhibition

A). Schematic showing the competitive interaction between Gβγ and synaptotagmin at the SNARE complex in presynaptic terminals. Gβγ interferes with synaptotagmin binding at the C-terminal region of SNAP25.

B) Arrangement for paired recording between a presynaptic giant axon and its whole cell patch clamped postsynaptic target. Shown also is a confocal reconstruction of a presynaptic axon (blue) making synapses onto its postsynaptic target (yellow). Image shown at 3 levels of magnification.

C) Paired recording – top – presynaptic action potential and bottom postsynaptic EPSC in control (black) and 5-HT (blue; note the chemical component, but not the early electrical component, is inhibited by 5-HT). D) Similar recording to C) in which $G\beta\gamma$ is injected into the presynaptic terminal (green) to inhibit synaptic responses. E) The effect of 5-HT is blocked by presynaptic injection of the ct-GRK2 to buffer $G\beta\gamma$. Ea) control effect of 5-HT prior to ct-GRK2 injection – 5-HT inhibits the chemical component of the EPSC. Eb) After ct-GRK2 injection, the effect of 5-HT is blocked.

Figure 3. GPCRs target primed vesicle SNAREs late in the exocytotic/endocytotic cycle
A) schematic showing the targets for BoNT/A and B on the SNARE complex adapted from [148].

B) graph of the amplitude of synaptic responses before and after presynaptic BoNT/B injection and after depletion of primed vesicles by a period of 1 Hz stimulation. BoNT/B has no immediate effect on EPSCs (purple triangles) after injection because primed vesicle SNARE complexes are inaccessible to the toxin. After loss of these primed vesicles by 1 Hz stimulation, EPSCs are abolished (purple squares). C) After presynaptic injection of BoNT/B, after a period during which BoNT/B has cleaved unprimed synaptobrevin, 5-HT can still inhibit EPSCs (blue circles), indicating 5-HT acts on primed vesicles. D) example traces from experiments shown in (C) control, after BoNT/B injection (purple) and after 5-HT (blue).

E) Experiment using BoNT/A as in (C) above. BoNT/A injection and subsequent depletion of primed vesicles with 1 Hz stimulation leaves approximately 50% of the EPSC intact. This remaining EPSC can no longer be inhibited by 5-HT indicating its target on the SNAP-25 C-terminus.

F) Histogram summarizing the effects of BoNTs on synaptic transmission and its modulation by 5-HT.

Figure 4. Gβγ inhibits synaptotagmin-SNARE interactions and SNARE-dependent lipid vesicle fusion

A) fluorescently labeled synaptotagmin 1 (C2AB) was applied above a t-SNARE containing lipid bilayer and fluorescence emission measured orthogonally and parallel to the excitation polarization angle. Addition of Ca²⁺ (200μM) caused an increase in fluorescence and anisotropy as the synaptotagmin interacted with the lipid membrane and t-SNAREs. Addition of Gβγ caused a reduction in both fluorescence and anisotropy. B) Dose response of purified Gβ₁γ₁ vs synaptotagmin 1 anisotropy. C) Diagram showing assay principle. Synaptobrevin-bearing liposomes containing the FRET pair NBD and rhodamine covalently attached to rhodamine react with unlabeled liposomes

containing t-SNARE complexes consisting of syntaxin1A and SNAP25. The increased surface area of the fused liposome reduces the quenching of NBD fluorescence by rhodamine and NBD fluorescence increases as a result.

D). NBD fluorescence traces over time for synaptotagmin 1 (10 μ M) and Ca²⁺ (1mM)-dependent liposome fusion in the presence of a series of concentrations of purified bovine G $\beta_1\gamma_1$ (concentrations from 100nM to 10 μ M were tested).

Figure 5. Modulatory properties of presynaptic 5-HT receptors on synaptic transmission and motor behavior

A) 5-HT inhibits excitatory synaptic transmission in the lamprey spinal cord, from both large descending command neurons – the reticulospinal neurons – and intraspinal excitatory interneurons

Ab) AMPA receptor-mediated EPSCs recorded in the presence of D-AP5 to block NMDA receptor-mediated responses are inhibited by 5-HT (red). The same dose of 5-HT did not inhibit NMDA receptor-mediated EPSCs (blue) recorded in NBQX to block AMPA receptors.

Ac) Repetitive stimulation causes accumulation of presynaptic Ca²⁺ and loss of 5-HT-mediated inhibition. Paired recording between a giant axon and a postsynaptic neuron. repetitive presynaptic action potentials cause a facilitating postsynaptic response (black). 5-HT (blue) inhibits at the start but not the end of the train.

B) The spinal motor circuitry activated by descending reticulospinal axons generates oscillations across the midline and a traveling wave along the rostro-caudal axis. The neural output that causes this movement is generated by spinal circuits including the excitatory synapses shown in (A). This can be activated by stimulation of the brainstem region that causes excitation of reticulospinal neurons. Shown in the schematic (Ca) The isolated brain-spinal cord preparation in which stimulation of the brainstem evokes fictive locomotion of

alternating activity in left-right pairs of ventral roots. A split bath allows application of drugs selectively to the spinal compartment.

Cb) Stimulation of the MLR in the brainstem evokes episodes of spinal fictive locomotion.

Cc) application of the selective 5-HT_{1B/1D} agonist L694-247, slows the alternating pattern without altering total output spiking.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript